Nebivolol Teva (Nebivolol Hydrochloride)

Nebivolol is a selective β1‑adrenergic antagonist used in the management of cardiovascular conditions.

• Essential hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Stage 1 hypertension: achieves target blood pressure when lifestyle measures are insufficient.
• Stage 2 hypertension: provides additional pressure reduction in patients requiring multiple agents.

• Nebivolol selectively blocks β1‑adrenergic receptors in cardiac tissue, decreasing heart rate and contractility, which reduces cardiac output. Concurrently, it stimulates endothelial nitric‑oxide release, causing vasodilation and further lowering systemic vascular resistance, resulting in an overall antihypertensive effect.

Nebivolol may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Headache: mild to moderate pain often occurring early in therapy.
• Dizziness or light‑headedness: related to blood pressure reduction.
• Fatigue: general tiredness, especially after dose initiation.
• Bradycardia: slower than normal heart rate.
• Peripheral edema: mild swelling of ankles or feet.
• Nasal congestion: sensation of a blocked nose.

Serious or Rare Side Effects

• Severe bradycardia: heart rate dropping to dangerously low levels.
• Atrioventricular block: impaired electrical conduction requiring monitoring.
• Bronchospasm: airway constriction, particularly in asthmatic patients.
• Allergic reactions: rash, itching, or anaphylaxis.
• Hepatic dysfunction: abnormal liver enzymes or jaundice.
• Acute heart failure exacerbation: worsening symptoms of cardiac insufficiency.

Before initiating Nebivolol, consider patient‑specific factors and monitor appropriately.

• Renal impairment: dose may need adjustment and renal function should be monitored.
• Hepatic impairment: use with caution; monitor liver enzymes.
• Asthma or COPD: avoid or use only if benefits outweigh risks due to β‑blockade.
• Pregnancy: safety not established; avoid unless clearly needed.
• Concomitant AV‑nodal blockers: monitor heart rate and rhythm closely.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid)

• Other β‑blockers: additive bradycardia and hypotension.
• Calcium channel blockers (verapamil, diltiazem): increased risk of AV block.
• Clonidine: abrupt withdrawal may cause rebound hypertension.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: may enhance hypotensive effect.
• Diuretics: risk of orthostatic hypotension and electrolyte imbalance.
• NSAIDs: may reduce antihypertensive efficacy.
• Antidiabetic agents: may mask hypoglycemia symptoms.